Harvard Bioscience, Inc. · NASDAQ:HBIO
Harvard Bioscience — Investor Presentation (November 2023)
18 slides from Harvard Bioscience's investor presentation, Nov 16, 2023
Slide 1: HBIO Investor Overview
Enabling discovery, safety and production of tomorrow’s therapeutics HBIO Investor Overview Jim Green, Chairman, President & CEO November 16, 2023
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified b
Slide 3: Company Profile
Most trusted partner of leading academic research institutions, contract research organizations, pharmaceutical and bio-techs in the discovery, production, and safety & regulatory compliance of tomorrow’s life-saving therapies. COMPANY PROFILE ▪ Global sales footprint, 3 core manufacturing facilitie
Slide 4: Harvard Bioscience Highlights
Harvard Bioscience Highlights DIVERSIFIED CUSTOMER / REVENUE Essential, secular growth markets, high Growing global marquee customer MODEL barriers, few competitors base Systems & Software Global sales, application science and service Highly effective sales channel structure supported by elite scien
Slide 5: Sales and Earnings Trends
Sales and Earnings Trends FY23 revenue growth projected to resume; recovery to consistent and growing adjusted EBITDA margins REVENUES Portfolio Optimization ADJUSTED EBITDA & EBITDA MARGINS* Supply Chain challenges $ IN MILLIONS FY23 Covid-19 Guidance *** ~ Flat $113.3 $0.4M** $ 5.5** FY23 Guidance
Slide 6: Today’s Global Footprint
Today’s Global Footprint CELLULAR & PRE- MOLECULAR CLINICAL Stuttgart, Germany SYSTEMS CELLULAR & Minneapolis MOLECULAR AND HBIO HEADQUARTERS Boston Core Operating Site 12-31-18 11-1-23 Sales Office / Small Centers of Excellence Employees* 547 430 Sites 14 8 *Headcount is approximate 6
Slide 7: Serving Well-funded, High-growth Secular Markets Demographic Tailwinds
Serving Well-funded, High-growth Secular Markets Demographic Tailwinds DRIVERS Rising incidence of disease – Increased demand for research tools, Increased funding for research devices and systems that improve cardiac, cancer, immunology, and development of advanced efficiency & productivity and ena
Slide 8: Blue Chip Customer Base
Blue Chip Customer Base CONTRACT ACADEMIC BIOTECH, RESEARCH RESEARCH PHARMACEUTICAL ORGANIZATIONS • Scientific Research labs primarily • Pre-clinical studies to determine • Perform early discovery and then government & grant funded safety and efficacy of new transition from discovery through pre- ph
Slide 9: Extend Technology Leadership in Academic Research & Discovery
Extend Technology Leadership in Academic Research & Discovery Research & Discovery Pre-Clinical Safety & Toxicology Bio-Production MOLECULES CELLS ORGANOIDS/ PRECLINICAL CLINICAL ORGANS Adapt Technologies to High Volume CRO & Bioproduction Applications 9
Slide 10: 2023-24 Strategic Growth Drivers
2023-24 Strategic Growth Drivers ACCELERATING REVENUE GROWTH LEVERAGE THE BASE EXPAND INDUSTRIAL APPS ADAPT TO BIO-PRODUCTION INNOVATE CELLULAR Maintain leadership in Expand GLP Leverage Technology Leverage leadership in Preclinical Telemetry Ponemah Enterprise Leadership in MEAs, Advance State of a
Slide 11: Leverage the Base
Leverage the Base Expand our Industry Leading Telemetry & Ponemah Data Management Platform Just introduced at 2023 Society for Neuroscience SoHo™ Next Generation Telemetry Platform • Supports simultaneous multi-animal telemetry in a more natural shared housing environment • Builds on our market lead
Slide 12: Expand High Volume Industrial Applications
Expand High Volume Industrial Applications Builds on Our Industry Leading Telemetry & Ponemah Data Management Platform LAN Just introduced at 2023 Society User‘s computer for Neuroscience (local or remote) Network Router Ponemah Actimetry & Acquisition/Analysis Switch SW Target Customers: CROs, Phar
Slide 13: Adapt to Bio-Production: BTX Electroporation as a Bridge to Bio-Production
Adapt to Bio-Production: BTX Electroporation as a Bridge to Bio-Production HBIO IS A PIONEER IN ELECTROPORATION AND ELECTROFUSION DRIVING NOVEL DISCOVERIES IN DRUG CREATION Applications Electroporation / Electrofusion Systems • Cell modification, CAR T-Cell creation, CGT Drug Discovery Configuration
Slide 14: Innovate: Mesh MEA Organoid Platform
Innovate: Mesh MEA (Micro Electrode Array) Organoid Platform Just introduced at 2023 MOVING TO HUMAN & PATIENT-DERIVED ORGANOIDS Society for Neuroscience Today’s Immortalized Animal Drug Testing Cells Model Future Human or Drug Testing Patient Derived Organoids • Human organoid as early proxy for an
Slide 15: Investment Thesis: Deliver Strong, Profitable, Long-Term Growth
Investment Thesis: Deliver Strong, Profitable, Long-Term Growth NEW PRODUCT INTRODUCTIONS FOCUSED ON TOP-LINE GROWTH & RECURRING REVENUE LARGE, LOYAL CUSTOMER BASE IN DRUG RESEARCH & DISCOVERY, SAFETY & REGULATORY AND BIO-PRODUCTION MARKETS FOCUSED ON LONG TERM TOPLINE GROWTH WITH 60% GROSS MARGINS
Slide 16: Thank You
Enabling discovery, safety and production of tomorrow’s therapeutics Thank You
Slide 17: Appendix
Appendix: 1 7 17
Slide 18: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures HARVARD BIOSCIENCE, INC. Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands) Year Ended Year Ended Year Ended Q3 YTD'22 Q3 YTD'23 31-Dec-20 31-Dec-21 31-Dec-22 30-Sep-22 30-Sep-23 GAAP net loss ($7,810) ($288) ($9,516) ($7,850) (
Harvard Bioscience — Investor Presentation (November 2023) on 6ix